291 related articles for article (PubMed ID: 12060400)
1. Incidence and risk factors associated with a second squamous cell carcinoma or basal cell carcinoma in psoralen + ultraviolet a light-treated psoriasis patients.
Katz KA; Marcil I; Stern RS
J Invest Dermatol; 2002 Jun; 118(6):1038-43. PubMed ID: 12060400
[TBL] [Abstract][Full Text] [Related]
2. High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients.
Lim JL; Stern RS
J Invest Dermatol; 2005 Mar; 124(3):505-13. PubMed ID: 15737190
[TBL] [Abstract][Full Text] [Related]
3. Ultraviolet exposure as the main initiator of p53 mutations in basal cell carcinomas from psoralen and ultraviolet A-treated patients with psoriasis.
Seidl H; Kreimer-Erlacher H; Bäck B; Soyer HP; Höfler G; Kerl H; Wolf P
J Invest Dermatol; 2001 Aug; 117(2):365-70. PubMed ID: 11511317
[TBL] [Abstract][Full Text] [Related]
4. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study.
Stern RS; Liebman EJ; Väkevä L
J Natl Cancer Inst; 1998 Sep; 90(17):1278-84. PubMed ID: 9731734
[TBL] [Abstract][Full Text] [Related]
5. The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study.
Nijsten TE; Stern RS
J Invest Dermatol; 2003 Aug; 121(2):252-8. PubMed ID: 12880415
[TBL] [Abstract][Full Text] [Related]
6. The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis.
Stern RS; Bagheri S; Nichols K;
J Am Acad Dermatol; 2002 Jul; 47(1):33-9. PubMed ID: 12077578
[TBL] [Abstract][Full Text] [Related]
7. The ultraviolet fingerprint dominates the mutational spectrum of the p53 and Ha-ras genes in psoralen + ultraviolet A keratoses from psoriasis patients.
Wolf P; Kreimer-Erlacher H; Seidl H; Bäck B; Soyer HP; Kerl H
J Invest Dermatol; 2004 Jan; 122(1):190-200. PubMed ID: 14962108
[TBL] [Abstract][Full Text] [Related]
8. High frequency of ultraviolet mutations at the INK4a-ARF locus in squamous cell carcinomas from psoralen-plus-ultraviolet-A-treated psoriasis patients.
Kreimer-Erlacher H; Seidl H; Bäck B; Cerroni L; Kerl H; Wolf P
J Invest Dermatol; 2003 Apr; 120(4):676-82. PubMed ID: 12648234
[TBL] [Abstract][Full Text] [Related]
9. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.
Paul CF; Ho VC; McGeown C; Christophers E; Schmidtmann B; Guillaume JC; Lamarque V; Dubertret L
J Invest Dermatol; 2003 Feb; 120(2):211-6. PubMed ID: 12542524
[TBL] [Abstract][Full Text] [Related]
10. Psoriasis, its treatment, and cancer in a cohort of Finnish patients.
Hannuksela-Svahn A; Pukkala E; Läärä E; Poikolainen K; Karvonen J
J Invest Dermatol; 2000 Mar; 114(3):587-90. PubMed ID: 10692122
[TBL] [Abstract][Full Text] [Related]
11. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study.
Stern RS;
J Am Acad Dermatol; 2012 Apr; 66(4):553-62. PubMed ID: 22264671
[TBL] [Abstract][Full Text] [Related]
12. Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation.
Licata AG; Wilson LD; Braverman IM; Feldman AM; Kacinski BM
Arch Dermatol; 1995 Apr; 131(4):432-5. PubMed ID: 7726585
[TBL] [Abstract][Full Text] [Related]
13. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study.
Nijsten TE; Stern RS
J Am Acad Dermatol; 2003 Oct; 49(4):644-50. PubMed ID: 14512910
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous squamous-cell carcinoma in patients treated with PUVA.
Stern RS; Laird N; Melski J; Parrish JA; Fitzpatrick TB; Bleich HL
N Engl J Med; 1984 May; 310(18):1156-61. PubMed ID: 6709010
[TBL] [Abstract][Full Text] [Related]
15. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.
Asgari MM; Ray GT; Geier JL; Quesenberry CP
J Am Acad Dermatol; 2017 Apr; 76(4):632-638. PubMed ID: 28162854
[TBL] [Abstract][Full Text] [Related]
16. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study.
Marcil I; Stern RS
Lancet; 2001 Sep; 358(9287):1042-5. PubMed ID: 11589933
[TBL] [Abstract][Full Text] [Related]
17. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.
Peyrin-Biroulet L; Khosrotehrani K; Carrat F; Bouvier AM; Chevaux JB; Simon T; Carbonnel F; Colombel JF; Dupas JL; Godeberge P; Hugot JP; Lémann M; Nahon S; Sabaté JM; Tucat G; Beaugerie L;
Gastroenterology; 2011 Nov; 141(5):1621-28.e1-5. PubMed ID: 21708105
[TBL] [Abstract][Full Text] [Related]
18. Nonmonoclonal PTCH gene mutations in psoralen plus UVA-associated basal cell carcinomas.
Heitzer E; Wolf P
J Invest Dermatol; 2008 Mar; 128(3):746-9. PubMed ID: 18059486
[No Abstract] [Full Text] [Related]
19. Cumulative risks and rates of subsequent basal cell carcinomas in the Netherlands.
Flohil SC; Koljenović S; de Haas ER; Overbeek LI; de Vries E; Nijsten T
Br J Dermatol; 2011 Oct; 165(4):874-81. PubMed ID: 21711333
[TBL] [Abstract][Full Text] [Related]
20. Occurrence of other cancers among patients with prior basal cell and squamous cell skin cancer.
Karagas MR; Greenberg ER; Mott LA; Baron JA; Ernster VL
Cancer Epidemiol Biomarkers Prev; 1998 Feb; 7(2):157-61. PubMed ID: 9488591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
